Zynerba Pharmaceuticals
Zynerba Pharmaceuticals is a Devon, Pennsylvania-based, delisted clinical-stage pharmaceutical company founded in 2007 that develops transdermal cannabidiol (CBD) gel therapies for neuroscience indications including Fragile X syndrome and 22q11.2 deletion syndrome.
- Company typePublic
- Founded2007
- HeadquartersDevon, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Zynerba Pharmaceuticals does
Zynerba Pharmaceuticals, Inc. is a Devon, Pennsylvania-based clinical-stage pharmaceutical developer founded in 2007 that builds transdermal (dermal-application) drug-delivery products for neuroscience indications. The company's core technology is a permeation-enhanced cannabidiol gel (ZYN002) designed to deliver CBD through the skin to treat central nervous system disorders, with lead development focus on Fragile X syndrome and 22q11.2 deletion syndrome. The asset was advanced by partner Harmony Biosciences, which paused Fragile X development in 2025 following a Phase 3 trial failure and is reviewing potential follow-on work in 22q11.2 deletion syndrome.
The company is structured as a for-profit corporation that was previously listed on NASDAQ under ticker ZYNE and is now delisted, with a remaining headcount of 1–10 employees. The leadership team is led by founder Audra L. Stinchcomb, CEO and Chairman Armando Anido, President Terri Sebree, and CFO/VP Corporate Development James E. Fickenscher. Capitalization history includes an early 2007 round backed by Keyhorse Capital and a 2014 financing of $13,000,000 led by Perceptive Advisors; no subsequent funding events are disclosed in the input.
The business model is pre-commercial: Zynerba has historically relied on equity financing and partnership/out-licensing arrangements to fund clinical development rather than direct product sales. With no approved product, no commercial sales force, and post-delisting private status, the company's revenue mechanics are effectively limited to residual licensing milestones or collaboration economics from third-party development of its pipeline.
Zynerba Pharmaceuticals firmographics
Firmographics- Name
- Zynerba Pharmaceuticals
- Legal name
- Harmony Biosciences Management, Inc.
- Website
- https://zynerba.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Zynerba Pharmaceuticals is a Devon, Pennsylvania-based, delisted clinical-stage pharmaceutical company founded in 2007 that develops transdermal cannabidiol (CBD) gel therapies for neuroscience indications including Fragile X syndrome and 22q11.2 deletion syndrome.
- Ownership category
- akta.pro rank
Zynerba Pharmaceuticals industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Zynerba Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Devon
- HQ country
- United States
- HQ region
- North America
Markets served
Zynerba Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Zynerba Pharmaceuticals product offering
Product offeringCore offering
Zynerba Pharmaceuticals, Inc. develops pharmaceutical products using proprietary transdermal (dermal) delivery technology to treat neuroscience disorders. The company's lead investigational candidate is ZYN002, a cannabidiol gel, which has been evaluated for fragile X syndrome and 22q11.2 deletion syndrome.
Differentiator
Problem solved
Functional benefit
Brands
- Newrology: A fresh approach to helping patients thrive, representing Harmony Biosciences' patient-focused drug development model.
Products and services
- ZYN002 (cannabidiol gel) Proprietary transdermal cannabidiol gel formulation developed as an investigational treatment for patients with fragile X syndrome and 22q11.2 deletion syndrome. Designed to deliver cannabidiol through the skin for central nervous system disorders.
Companies that use Zynerba Pharmaceuticals
Customer profileIdeal customer profiles1 record
Zynerba Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Zynerba Pharmaceuticals partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights1 record
Zynerba Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Sage Therapeutics: CNS specialty pharma developing therapies for rare neurological and psychiatric conditions (e.g., Zurzuvae). Comparable in CNS rare-disease focus, branded-innovator positioning, and clinical-stage development.
- Jazz Pharmaceuticals: Specialty CNS pharma with the leading cannabinoid-derived product (Epidiolex, via GW Pharmaceuticals acquisition) plus a broader neurology/rare-disease portfolio. Most directly comparable to Zynerba as a CBD-based CNS drug developer with branded, rare-disease assets.
- GW Pharmaceuticals: Pioneer in cannabinoid-based therapeutics with Epidiolex for rare epilepsies (now part of Jazz). Historically a direct peer to Zynerba as a CBD-based CNS drug developer focused on rare neurological indications via a transdermal/oral delivery approach.
- Axsome Therapeutics: CNS-focused specialty pharma with commercialized neurology/psychiatry products. Comparable in CNS specialty positioning, branded-pharma approach, and development-to-commercialization trajectory.
- Marinus Pharmaceuticals: CNS-focused specialty pharma commercializing ganaxolone for rare epilepsies. Comparable therapeutic-area focus (rare neurological disorders) and clinical/commercial-stage profile to Zynerba's CNS ambitions.
- Relmada Therapeutics: CNS specialty pharma that recently expanded its pipeline via the Sepranolone acquisition from Asarina Pharma. Comparable in CNS specialty focus and active business-development approach to in-licensing rare-disease CNS assets.
- Corbus Pharmaceuticals: Clinical-stage company developing cannabinoid-derived therapeutics for rare diseases including CNS indications. Comparable to Zynerba in cannabinoid-based modality, rare-disease focus, and clinical-stage profile.
- Harmony Biosciences: Public CNS specialty pharma that was actively developing ZYN002 (cannabidiol gel) before pausing after Phase 3 failure. The closest therapeutic-area comparable and the most recent commercialization-stage partner to Zynerba.
Emerging players
- InMed Pharmaceuticals: Early-stage cannabinoid therapeutic developer focused on rare diseases including CNS applications. Comparable in cannabinoid-based therapeutic modality and emerging-stage positioning, though with broader pipeline scope.
Broad incumbents
- Biogen: Large established neuroscience-focused pharmaceutical company with a broad CNS/neurology portfolio. Comparable in therapeutic focus but with vastly greater scale, commercial infrastructure, and pipeline breadth relative to Zynerba.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Zynerba Pharmaceuticals social profiles
Digital presenceZynerba Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Zynerba Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles4 records
Zynerba Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Zynerba Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Zynerba Pharmaceuticals
What does Zynerba Pharmaceuticals do?
Zynerba Pharmaceuticals, Inc. develops pharmaceutical products using proprietary transdermal (dermal) delivery technology to treat neuroscience disorders. The company's lead investigational candidate is ZYN002, a cannabidiol gel, which has been evaluated for fragile X syndrome and 22q11.2 deletion syndrome.
Is Zynerba Pharmaceuticals a public or private company?
Zynerba Pharmaceuticals is a public company. It is classified as unknown and is currently operating.
When was Zynerba Pharmaceuticals founded?
Zynerba Pharmaceuticals was founded in 2007. It employs 1 to 10 people.
Where is Zynerba Pharmaceuticals based?
Zynerba Pharmaceuticals is headquartered in Devon, United States, in the North America region.
Who are Zynerba Pharmaceuticals's main competitors?
Direct peers on record are Sage Therapeutics, Jazz Pharmaceuticals, GW Pharmaceuticals, Axsome Therapeutics, Marinus Pharmaceuticals, Relmada Therapeutics, Corbus Pharmaceuticals and Harmony Biosciences. InMed Pharmaceuticals is listed as an emerging player. Biogen is listed as a broad incumbent.
Does Zynerba Pharmaceuticals have an API?
No public API is recorded for Zynerba Pharmaceuticals.
What industry is Zynerba Pharmaceuticals in?
Zynerba Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.